12:00 AM
Sep 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

LL-37: Phase I/II started

Pergamum began a double-blind, placebo-controlled, Swedish Phase I/II trial to evaluate 3 doses of LL-37 for 1...

Read the full 63 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >